NeurologyLive® Launches Advances in the Treatment of Alzheimer’s Disease Video Series

The expert ‘Peer Exchange’ panel will discuss the evolving landscape of Alzheimer’s treatment

CRANBURY, N.J.–(BUSINESS WIRE)–NeurologyLive®, a multimedia platform dedicated to providing health care professionals treating neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, presents its most recent “Peer Exchange” panel discussion, “Advances in the Treatment of Alzheimer’s Disease.” The video series welcomes several experts in the field of Alzheimer’s disease (AD) who will discuss the causes and detection of AD as well as updates on treatment.

“Alzheimer’s disease is an irreversible brain disorder that affects an individual’s memory and ability to carry out the simplest tasks,” said Michael J. Hennessy Jr., president of MJH Life Sciences™, parent company of NeurologyLive®. “During this video series, our experts come together to discuss advances in diagnosis and clinical trials and provide perspective on how new data can be applied to the treatment of Alzheimer’s disease.”

The panel features five distinguished experts:

• Jeffrey L. Cummings, M.D., Sc.D., research professor, department of brain health, UNLV and founding director, Cleveland Clinic Lou Ruvo Center for Brain Health, as moderator,
• Alireza Atri, M.D., Ph.D., medical director, Banner Sun Health Research Institute.
• Richard S. Isaacson, M.D., director, Alzheimer’s Prevention Clinic, Weill Cornell Medical College and NewYork-Presbyterian
• Elaine R. Peskind, M.D., Friends of the Alzheimer’s Research Endowed Professor of Psychiatry University of Washington School of Medicine.
• Marwan Sabbagh, M.D., director, Cleveland Clinic Lou Ruvo Center for Brain Health.

This “Peer Exchange” series begins with a discussion of the possible causes of the disease, as well as strategies for detection. The conversation moves on to discuss diagnosis and the multidisciplinary approach necessary for treating AD. Additional segments will explore addressing cognitive impairment in AD and the evolving precision targets for the disease.

For more information and to view the video series, click here.

About NeurologyLive®

A multimedia platform for health care professionals treating neurological diseases, NeurologyLive® delivers direct access to practice-changing news and expert insight from top medical conferences and researchers to improve the lives of patients with neurological diseases such as dementia and Alzheimer’s disease, epilepsy, headache and migraine, movement disorders, multiple sclerosis, neuromuscular diseases, sleep medicine and stroke. The NeurologyLive® platform offers an in-depth look at the hundreds of new treatments in development with ever-expanding mechanisms of action, all during an unprecedented time of growing demand for neurology expertise. The NeurologyLive® platform also connects visitors with the most up-to-date clinical trial results, Food and Drug Administration approvals, practice-changing research and expert insight. NeurologyLive® is a brand of MJH Life Sciences™, the largest privately held, independent full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.

Contacts

NeurologyLive® Media Contact

John Patricolo, 609-325-4630

[email protected]